Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy

Pediatric Transplantation

Volumn 9, Issue 2, 2005, Pages 249-253

  Al Akash, Samhar I ^a   Al Makadma, Abdulkarim S ^a   Al Omari, Mohammad G ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Epstein Barr virus; Immunosuppression; Post transplant lymphoproliferative disease; Rituximab

Indexed keywords

DIPHENHYDRAMINE; GANCICLOVIR; HYDROCORTISONE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ADENOID; ARTICLE; CASE REPORT; CHILD; FEMALE; HUMAN; HYPEROXALURIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; TONSIL DISEASE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; RECURRENCE; SIROLIMUS;

EID: 16444381590     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00253.x     Document Type: Article

References (17)

1. GREEN M. Management of Epstein-Barr Virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
2. FINN L, REYES J. BUENO J, YUNIS E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299-309.
3. DROR Y, GREENBERG M, TAYLOR G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67: 990-998.
4. OPELZ G, DOHLER B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222-230.
5. GUTHERY SL, HEUBI JE, BUCUVALAS JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75: 987-993.
6. LOREN AW, PORTER DL, STADTMAUER EA, TSAI DE. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003; 31: 145-155.
7. STARZL TE, NALESNIK MA, PORTER KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
8. TSAI DE, HARDY CL, TOMASZEWSKI JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
9. SERINET MO, JACQUEMIN E, HABES D, DEBRAY D, FABRE D, BERNARD O. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002; 34: 389-393.
10. BERNEY T, DELIS S, KATO T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002; 74: 1000-1006.
11. VENZKE A, GANSHOW R, GRABHORN E, ROGIERS X, BURDELSKI M. Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy. Pediatr Transpl 2003; 7: 404-407.
12. SHROFF R, REES L. The post-transplant lymphoproliferative disorder - a literature review. Pediatr Nephrol 2004; 19: 369-377.
13. KÖPF S, TÖNSHOFF B. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatrix renal transplant recipients. Pediatr Nephrol 2004; 19: 365-368.
14. MAJEWSKI M, KORECKA M, JOERGENSEN J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 5: 1710-1717.
15. NEPOMUCENO RR, BALATONI CE, NATKUNAM Y, SNOW AL, KRAMS SM, MARTINEZ OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-4480.
16. BEATTY PR, KRAMS SM, ESQUIVEL CO, MARTINEZ OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 1998; 65: 1248-1255.
17. GARCIA VD, BONAMIGO-FILHO JS, NEUMANN J, et al. Rituximab and Rapamycin for posttransplant lymphoproliferative disease treatment: Report of three cases. Transpl Proc 2002; 34: 2993-2995.